Hybrid Quantum Dot−Fatty Ester Stealth Nanoparticles: Toward Clinically Relevant in Vivo Optical Imaging of Deep Tissue
Source abstract
Abstract
Despite broad applications of quantum dots (QDs) in vitro, severe toxicity and dominant liver uptake have limited their clinical application. QDs that excite and emit in the ultraviolet and visible regions have limited in vivo applicability due to significant optical interference exerted by biological fluids and tissues. Hence we devised a new biocompatible hybrid fluorophore composed of near-infrared-emitting PbSe quantum dots encapsulated in solid fatty ester nanoparticles (QD-FEN) for in vivo imaging. The quantum yield and tissue penetration depth of the QD-FEN were characterized, and their biological fate was examined in a breast tumor-bearing animal model. It was found for the first time that chemical modification of the headgroup of QD-encapsulating organic fatty acids was a must as these groups quenched the photoluminescence of PbSe nanocrystals. The use of fatty esters enhanced aqueous quantum yields of PbSe QDs up to ∼45%, which was 50% higher than that of water-soluble PbSe nanocrystals in an aqueous medium. As a result, a greater than previously reported tissue penetration depth of fluorescence was recorded at 710 nm/840 nm excitation/emission wavelengths. The QD-FEN had much lower short-term cytotoxicity compared to nonencapsulated water-soluble QDs. More importantly, reduced liver uptake, increased tumor retention, lack of toxic response, and nearly complete clearance of QD-FEN from the tested animals was demonstrated. With a combination of near-infrared spectral properties, enhanced optical properties,and significantly improved biosafety profile, this novel hybrid nanoparticulate fluorophore system demonstrably provides real-time, deep-tissue fluorescent imaging of live animals, laying a foundation for further development toward clinical application.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Quantum Dots Synthesis And Properties · Nanoplatforms for cancer theranostics · Carbon and Quantum Dots Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Leslie L. Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario, Canada, M5S 3M2
Department of Physics, Ryerson University, 350 Victoria Street, Toronto, Ontario, Canada, M5B 2K3
NRC Steacie Institute for Molecular Sciences, National Research Council of Canada, 100 Sussex Drive, Ottawa, Ontario, Canada, K1A 0R6
Department of Medical Biophysics, University Health Network, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, Canada, M5G 2M9
References (35)
Show source-provided references
1. Holm B. A. · Mol. Cryst. Liq. Cryst. Sci. Technol., Sect. A · 2002 · 374 · 58910.1080/713738279 ↗
2. Aswathy R. G. · Anal. Bioanal. Chem. · 2010 · 397 · 141710.1007/s00216-010-3643-6 ↗
3. Altinoglu E. I. · Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. · 2010 · 2 · 46110.1002/wnan.77 ↗
4. Smith A. M. · Nat. Nanotechnol. · 2009 · 4 · 71010.1038/nnano.2009.326 ↗
5. Ntziachristos V. · Eur. Radiol. · 2003 · 13 · 19510.1007/s00330-002-1524-x ↗
6. Ghoroghchian P. P. · Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. · 2009 · 1 · 15610.1002/wnan.7 ↗
7. Prasad P. N. · 200310.1002/0471465380 ↗
8. Santra S. · 2007 · 44
9. Ballou B. · Bioconjugate Chem. · 2007 · 18 · 38910.1021/bc060261j ↗
10. Kim S. · Nat. Biotechnol. · 2004 · 22 · 9310.1038/nbt920 ↗
11. Zimmer J. P. · J. Am. Chem. Soc. · 2006 · 128 · 252610.1021/ja0579816 ↗
12. Cai W. · Nano Lett. · 2006 · 6 · 66910.1021/nl052405t ↗
13. Diagaradjane P. · Clin. Cancer Res. · 2008 · 14 · 73110.1158/1078-0432.CCR-07-1958 ↗
14. Du H. · Nano Lett. · 2002 · 2 · 132110.1021/nl025785g ↗
15. Evans C. M. · Nano Lett. · 2008 · 8 · 289610.1021/nl801685a ↗
16. Azzazy H. M. · Clin. Biochem. · 2007 · 40 · 91710.1016/j.clinbiochem.2007.05.018 ↗
17. Cho S. J. · Langmuir · 2007 · 23 · 197410.1021/la060093j ↗
18. Hardman R. A · Environ. Health Perspect. · 2006 · 114 · 16510.1289/ehp.8284 ↗
19. Bentolila L. A. · J. Nucl. Med. · 2009 · 50 · 49310.2967/jnumed.108.053561 ↗
20. Yang R. S. · Environ. Health Perspect. · 2007 · 115 · 133910.1289/ehp.10290 ↗
21. Liu W. · J. Biomed. Mater. Res. A · 2008 · 84 · 101810.1002/jbm.a.31205 ↗
22. Ouyang J. · ACS Appl. Mater. Interfaces · 2010
23. Gabizon A. A. · Clin. Cancer Res. · 2001 · 7 · 223
24. Benson R. C. · J. Chem. Eng. Data · 1977 · 22 · 37910.1021/je60075a020 ↗
25. Hoshi M. · J. Lipid Res. · 1973 · 14 · 59910.1016/S0022-2275(20)36868-1 ↗
26. De Grand A. M. · J. Biomed. Opt. · 2006 · 11 · 01400710.1117/1.2170579 ↗
27. Abramoff M. D. · Biophoton. Int. · 2004 · 11 · 36
28. Patocka J. · Acta Med. (Hradec Kralove) · 2003 · 46 · 6510.14712/18059694.2019.8 ↗
29. MacFarquhar J. K. · Arch. Intern. Med. · 2010 · 170 · 25610.1001/archinternmed.2009.495 ↗
30. O’Brien P. J. · Chem. Biol. Interact. · 2004 · 150 · 9710.1016/j.cbi.2004.09.003 ↗
31. Shuhendler A. J. · Breast Cancer Res. Treat. · 2010 · 119 · 25510.1007/s10549-008-0271-3 ↗
32. Wong H. L. · Eur. J. Pharm. Biopharm. · 2007 · 65 · 30010.1016/j.ejpb.2006.10.022 ↗
33. Mansur H. S. · Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. · 2010 · 2 · 11310.1002/wnan.78 ↗
34. Moldeus P. · Methods Enzymol. · 1978 · 52 · 6010.1016/S0076-6879(78)52006-5 ↗
35. Moridani M. Y. · Free Radical Biol. Med. · 2003 · 34 · 24310.1016/S0891-5849(02)01241-8 ↗